|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:XYZ_Pharma
|
|
gptkbp:affiliation
|
gptkb:Japanese_Pharmaceutical_Manufacturers_Association
|
|
gptkbp:awards
|
Innovation Award 2021
Best_Pharmaceutical_Company_2020
|
|
gptkbp:employees
|
1000+
|
|
gptkbp:financials
|
Revenue 2022: $500 million
Net Income 2022: $50 million
Assets 2022: $1 billion
Market Capitalization: $2 billion
|
|
gptkbp:founded
|
1950
|
|
gptkbp:headCoach
|
gptkb:Dr._Yamada
Mr._Suzuki
Mr._Watanabe
Ms._Sato
|
|
gptkbp:headOfMarketing
|
Ms._Tanaka
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nihon Pharmaceutical Co., Ltd.
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:keyPeople
|
CEO
|
|
gptkbp:market
|
gptkb:Asia
gptkb:Japan
Global
|
|
gptkbp:partnerships
|
gptkb:Osaka_University
gptkb:University_of_Tokyo
gptkb:Kyoto_University
|
|
gptkbp:patentCitation
|
Patent for Drug A
Patent for Drug B
Patent for Drug C
|
|
gptkbp:products
|
Prescription drugs
Over-the-counter drugs
|
|
gptkbp:researchFocus
|
Oncology
Neurology
Cardiovascular
|
|
gptkbp:researchInterest
|
gptkb:National_Institute_of_Health
gptkb:Japan_Agency_for_Medical_Research_and_Development
|
|
gptkbp:services
|
Manufacturing
Marketing
Research_and_Development
|
|
gptkbp:socialResponsibility
|
Environmental Sustainability Programs
Community_Health_Initiatives
Employee_Welfare_Programs
|
|
gptkbp:subsidiary
|
Nihon Pharmaceutical USA, Inc.
|
|
gptkbp:trademark
|
Trademark A
Trademark B
Trademark C
|
|
gptkbp:website
|
www.nihonpharma.co.jp
|